- Home
- PRGS vs MRUS Comparison
PRGS vs MRUS Comparison
Compare PRGS & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRGS
- MRUS
- Stock Information
- Founded
- PRGS 1981
- MRUS 2003
- Country
- PRGS United States
- MRUS Netherlands
- Employees
- PRGS N/A
- MRUS N/A
- Industry
- PRGS Computer Software: Prepackaged Software
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- PRGS Technology
- MRUS Health Care
- Exchange
- PRGS Nasdaq
- MRUS Nasdaq
- Market Cap
- PRGS 2.4B
- MRUS 2.7B
- IPO Year
- PRGS 1991
- MRUS 2016
- Fundamental
- Price
- PRGS $56.00
- MRUS $43.06
- Analyst Decision
- PRGS Buy
- MRUS Strong Buy
- Analyst Count
- PRGS 7
- MRUS 13
- Target Price
- PRGS $73.71
- MRUS $86.85
- AVG Volume (30 Days)
- PRGS 979.3K
- MRUS 872.0K
- Earning Date
- PRGS 03-31-2025
- MRUS 05-07-2025
- Dividend Yield
- PRGS 0.63%
- MRUS N/A
- EPS Growth
- PRGS N/A
- MRUS N/A
- EPS
- PRGS 1.27
- MRUS N/A
- Revenue
- PRGS $806,739,000.00
- MRUS $36,133,000.00
- Revenue This Year
- PRGS $30.62
- MRUS $26.81
- Revenue Next Year
- PRGS $2.94
- MRUS $23.85
- P/E Ratio
- PRGS $44.18
- MRUS N/A
- Revenue Growth
- PRGS 12.85
- MRUS N/A
- 52 Week Low
- PRGS $48.00
- MRUS $33.19
- 52 Week High
- PRGS $70.56
- MRUS $61.61
- Technical
- Relative Strength Index (RSI)
- PRGS 49.51
- MRUS 51.15
- Support Level
- PRGS $53.71
- MRUS $33.19
- Resistance Level
- PRGS $58.67
- MRUS $43.46
- Average True Range (ATR)
- PRGS 2.33
- MRUS 3.53
- MACD
- PRGS 0.08
- MRUS 0.34
- Stochastic Oscillator
- PRGS 61.43
- MRUS 80.53
About PRGS Progress Software Corporation (DE)
Progress Software Corporation provides software operate in one operating segment: software products for the development, deployment, and management of responsible, AI-powered applications and digital experiences. Following are products: Chef, Corticon, Data Direct, Developer Tools, Flowmon, Kemp LoadMaster, MarkLogic, MOVEit, OpenEdge, Semaphore, ShareFile, Sitefinity, WhatsUp Gold. Geographical regions include United States, Canada, EMEA, Latin America, and Asia Pacific.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.